1. First-in-Human Phase I Study of Envafolimab, a Novel Subcutaneous Single-Domain Anti-PD-L1 Antibody, in Patients with Advanced Solid Tumors. (27th May 2021) Authors: Papadopoulos, Kyriakos P.; Harb, Wael; Peer, Cody J.; Hua, Qiong; Xu, Siying; Lu, Haolan; Lu, Ni; He, Yue; Xu, Ting; Dong, Ruiping; Gong, John; Liu, David Journal: Oncologist Issue: Volume 26:Number 9(2021) Page Start: e1514 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. First‐in‐Human Phase I Study of Envafolimab, a Novel Subcutaneous Single‐Domain Anti‐PD‐L1 Antibody, in Patients with Advanced Solid Tumors. (27th May 2021) Authors: Papadopoulos, Kyriakos P.; Harb, Wael; Peer, Cody J.; Hua, Qiong; Xu, Siying; Lu, Haolan; Lu, Ni; He, Yue; Xu, Ting; Dong, Ruiping; Gong, John; Liu, David Journal: Oncologist Issue: Volume 26:Number 9(2021) Page Start: e1514 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗